Artwork for podcast Pathfinders in Biopharma
Compass trials mark a milestone moment for the psychedelics sector
Episode 36 • 21st July 2025 • Pathfinders in Biopharma • RBC Capital Markets
00:00:00 00:12:35

Share Episode

Shownotes

Compass Pathways CEO Kabir Nath believes psilocybin-based therapy could be transformational for patients with treatment-resistant depression—and his company is already preparing to deliver it at scale. Speaking at RBC Capital Markets’ Global Healthcare Conference, Nath shares his vision for Compass and the future of psilocybin therapy for treatment-resistant depression.

Follow

Links

Chapters

Video

More from YouTube